Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
84% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Debt-to-Equity 0.72
PFE's Debt-to-Equity is ranked lower than
75% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. PFE: 0.72 )
Ranked among companies with meaningful Debt-to-Equity only.
PFE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1  Med: 0.47 Max: 0.79
Current: 0.72
0.1
0.79
Debt-to-EBITDA 2.14
PFE's Debt-to-EBITDA is ranked lower than
56% of the 511 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. PFE: 2.14 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PFE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.88  Med: 1.88 Max: 2.89
Current: 2.14
0.88
2.89
Interest Coverage 11.39
PFE's Interest Coverage is ranked lower than
72% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 127.83 vs. PFE: 11.39 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.39
5.27
18.94
Piotroski F-Score: 7
Altman Z-Score: 2.42
Beneish M-Score: -2.61
WACC vs ROIC
8.18%
45.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 26.85
PFE's Operating Margin % is ranked higher than
91% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.71 vs. PFE: 26.85 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 26.85
14.53
29.44
Net Margin % 40.55
PFE's Net Margin % is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. PFE: 40.55 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 40.55
12.67
42.65
ROE % 35.46
PFE's ROE % is ranked higher than
95% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. PFE: 35.46 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 35.46
Current: 35.46
9.29
35.46
ROA % 12.40
PFE's ROA % is ranked higher than
84% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. PFE: 12.40 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.4
Current: 12.4
4.05
12.4
ROC (Joel Greenblatt) % 87.92
PFE's ROC (Joel Greenblatt) % is ranked higher than
95% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.46 vs. PFE: 87.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 87.92
Current: 87.92
40.74
87.92
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
53% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 6.7 Max: 19.2
Current: 4.7
-2.5
19.2
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 7.8 Max: 36.8
Current: -10.1
-10.1
36.8
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 6.35 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 4 Warning Signs with Pfizer Inc PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2018-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

PFE Guru Trades in Q1 2017

George Soros 31,200 sh (New)
David Carlson 650,000 sh (+116.67%)
Joel Greenblatt 944,660 sh (+24.40%)
John Paulson 407,500 sh (+15.70%)
Charles Brandes 6,018,005 sh (+14.16%)
Manning & Napier Advisors, Inc 719,433 sh (+5.18%)
Mairs and Power 4,871,107 sh (+3.09%)
Ken Fisher 32,759,530 sh (+1.72%)
Murray Stahl 70,082 sh (+0.98%)
John Buckingham 74,585 sh (+0.60%)
David Dreman 18,901 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Richard Pzena 2,217,509 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Jeff Auxier 84,868 sh (-0.73%)
Mario Gabelli 485,466 sh (-1.02%)
Ronald Muhlenkamp 33,034 sh (-2.80%)
Diamond Hill Capital 12,358,068 sh (-4.62%)
Barrow, Hanley, Mewhinney & Strauss 42,835,523 sh (-5.65%)
Pioneer Investments 8,844,361 sh (-6.67%)
Dodge & Cox 678,070 sh (-9.22%)
T Rowe Price Equity Income Fund 12,325,000 sh (-11.33%)
Jeremy Grantham 4,786,189 sh (-12.20%)
Lee Ainslie 19,833,477 sh (-13.21%)
Kahn Brothers 667,633 sh (-22.39%)
David Tepper 3,021,000 sh (-37.19%)
Paul Tudor Jones 6,400 sh (-41.28%)
NWQ Managers 1,313,554 sh (-42.39%)
Ray Dalio 62,095 sh (-78.00%)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (-9.19%)
» More
Q2 2017

PFE Guru Trades in Q2 2017

Jim Simons 7,990,141 sh (New)
Ray Dalio 183,203 sh (+195.04%)
David Dreman 29,210 sh (+54.54%)
Manning & Napier Advisors, Inc 836,028 sh (+16.21%)
John Buckingham 82,641 sh (+10.80%)
Barrow, Hanley, Mewhinney & Strauss 46,266,431 sh (+8.01%)
Pioneer Investments 9,482,233 sh (+7.21%)
Murray Stahl 73,976 sh (+5.56%)
Richard Pzena 2,332,274 sh (+5.18%)
Ken Fisher 34,035,362 sh (+3.89%)
Jeff Auxier 85,668 sh (+0.94%)
David Carlson 650,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Ronald Muhlenkamp 33,034 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Paul Tudor Jones Sold Out
David Tepper Sold Out
George Soros Sold Out
John Paulson Sold Out
Mairs and Power 4,868,827 sh (-0.05%)
Jeremy Grantham 4,783,377 sh (-0.06%)
Mario Gabelli 484,359 sh (-0.23%)
NWQ Managers 1,262,358 sh (-3.90%)
Diamond Hill Capital 11,331,723 sh (-8.31%)
Kahn Brothers 577,616 sh (-13.48%)
Charles Brandes 5,134,710 sh (-14.68%)
Dodge & Cox 575,228 sh (-15.17%)
T Rowe Price Equity Income Fund 10,237,000 sh (-16.94%)
Lee Ainslie 10,052,571 sh (-49.32%)
Joel Greenblatt 470,928 sh (-50.15%)
» More
Q3 2017

PFE Guru Trades in Q3 2017

Richard Pzena 4,008,274 sh (+71.86%)
Pioneer Investments 10,530,632 sh (+11.06%)
Ken Fisher 35,120,799 sh (+3.19%)
John Buckingham 84,630 sh (+2.41%)
Murray Stahl 74,956 sh (+1.32%)
Manning & Napier Advisors, Inc 838,007 sh (+0.24%)
David Carlson 650,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Dreman 29,210 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Ray Dalio Sold Out
Mario Gabelli 477,126 sh (-1.49%)
Diamond Hill Capital 11,128,596 sh (-1.79%)
Mairs and Power 4,766,771 sh (-2.10%)
Kahn Brothers 557,495 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 44,438,628 sh (-3.95%)
Jeff Auxier 81,068 sh (-5.37%)
T Rowe Price Equity Income Fund 9,565,000 sh (-6.56%)
Dodge & Cox 529,642 sh (-7.92%)
Jeremy Grantham 4,140,797 sh (-13.43%)
NWQ Managers 1,091,151 sh (-13.56%)
Ronald Muhlenkamp 27,494 sh (-16.77%)
Charles Brandes 3,821,667 sh (-25.57%)
Lee Ainslie 7,318,410 sh (-27.20%)
Jim Simons 5,608,741 sh (-29.80%)
Joel Greenblatt 21,817 sh (-95.37%)
» More
Q4 2017

PFE Guru Trades in Q4 2017

First Pacific Advisors 13,000 sh (New)
Steven Cohen 351,897 sh (New)
Tom Russo 1,900 sh (New)
Paul Tudor Jones 25,136 sh (New)
Joel Greenblatt 49,922 sh (+128.82%)
Pioneer Investments 19,093,990 sh (+81.32%)
First Eagle Investment 79,061 sh (+19.68%)
Richard Pzena 4,361,143 sh (+8.80%)
Ken Fisher 36,372,349 sh (+3.56%)
John Buckingham 87,558 sh (+3.46%)
David Carlson 650,000 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Murray Stahl 74,956 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ronald Muhlenkamp 27,494 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Lee Ainslie Sold Out
Kahn Brothers 554,606 sh (-0.52%)
Mairs and Power 4,717,328 sh (-1.04%)
NWQ Managers 1,072,487 sh (-1.71%)
Diamond Hill Capital 10,909,103 sh (-1.97%)
Jeremy Grantham 4,019,297 sh (-2.93%)
Charles Brandes 3,707,279 sh (-2.99%)
Jeff Auxier 78,618 sh (-3.02%)
Barrow, Hanley, Mewhinney & Strauss 42,212,028 sh (-5.01%)
Dodge & Cox 477,331 sh (-9.88%)
T Rowe Price Equity Income Fund 8,520,000 sh (-10.93%)
Mario Gabelli 386,031 sh (-19.09%)
David Dreman 14,424 sh (-50.62%)
Jim Simons 996,641 sh (-82.23%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.01%0.12%$35.06 - $37.2 $ 36.261%42,212,028
Ken Fisher 2017-12-31 Add 3.56%0.06%$35.06 - $37.2 $ 36.261%36,372,349
T Rowe Price Equity Income Fund 2017-12-31 Reduce -10.93%0.18%$35.06 - $37.2 $ 36.261%8,520,000
Richard Pzena 2017-12-31 Add 8.80%0.06%$35.06 - $37.2 $ 36.261%4,361,143
Charles Brandes 2017-12-31 Reduce -2.99%0.08%$35.06 - $37.2 $ 36.261%3,707,279
NWQ Managers 2017-12-31 Reduce -1.71%0.01%$35.06 - $37.2 $ 36.261%1,072,487
Kahn Brothers 2017-12-31 Reduce -0.52%0.02%$35.06 - $37.2 $ 36.261%554,606
Dodge & Cox 2017-12-31 Reduce -9.88%$35.06 - $37.2 $ 36.261%477,331
Mario Gabelli 2017-12-31 Reduce -19.09%0.02%$35.06 - $37.2 $ 36.261%386,031
First Eagle Investment 2017-12-31 Add 19.68%$35.06 - $37.2 $ 36.261%79,061
Joel Greenblatt 2017-12-31 Add 128.82%0.02%$35.06 - $37.2 $ 36.261%49,922
David Dreman 2017-12-31 Reduce -50.62%0.29%$35.06 - $37.2 $ 36.261%14,424
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -3.95%0.09%$32.67 - $35.99 $ 36.267%44,438,628
Ken Fisher 2017-09-30 Add 3.19%0.06%$32.67 - $35.99 $ 36.267%35,120,799
T Rowe Price Equity Income Fund 2017-09-30 Reduce -6.56%0.11%$32.67 - $35.99 $ 36.267%9,565,000
Richard Pzena 2017-09-30 Add 71.86%0.32%$32.67 - $35.99 $ 36.267%4,008,274
Charles Brandes 2017-09-30 Reduce -25.57%0.7%$32.67 - $35.99 $ 36.267%3,821,667
NWQ Managers 2017-09-30 Reduce -13.56%0.08%$32.67 - $35.99 $ 36.267%1,091,151
Kahn Brothers 2017-09-30 Reduce -3.48%0.1%$32.67 - $35.99 $ 36.267%557,495
Dodge & Cox 2017-09-30 Reduce -7.92%$32.67 - $35.99 $ 36.267%529,642
Mario Gabelli 2017-09-30 Reduce -1.49%$32.67 - $35.99 $ 36.267%477,126
Ronald Muhlenkamp 2017-09-30 Reduce -16.77%0.06%$32.67 - $35.99 $ 36.267%27,494
Joel Greenblatt 2017-09-30 Reduce -95.37%0.21%$32.67 - $35.99 $ 36.267%21,817
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 8.01%0.18%$31.75 - $34.34 $ 36.269%46,266,431
Ken Fisher 2017-06-30 Add 3.89%0.07%$31.75 - $34.34 $ 36.269%34,035,362
T Rowe Price Equity Income Fund 2017-06-30 Reduce -16.94%0.33%$31.75 - $34.34 $ 36.269%10,237,000
Charles Brandes 2017-06-30 Reduce -14.68%0.45%$31.75 - $34.34 $ 36.269%5,134,710
Richard Pzena 2017-06-30 Add 5.18%0.02%$31.75 - $34.34 $ 36.269%2,332,274
NWQ Managers 2017-06-30 Reduce -3.90%0.02%$31.75 - $34.34 $ 36.269%1,262,358
Kahn Brothers 2017-06-30 Reduce -13.48%0.53%$31.75 - $34.34 $ 36.269%577,616
Dodge & Cox 2017-06-30 Reduce -15.17%$31.75 - $34.34 $ 36.269%575,228
Mario Gabelli 2017-06-30 Reduce -0.23%$31.75 - $34.34 $ 36.269%484,359
Joel Greenblatt 2017-06-30 Reduce -50.15%0.21%$31.75 - $34.34 $ 36.269%470,928
David Dreman 2017-06-30 Add 54.54%0.19%$31.75 - $34.34 $ 36.269%29,210
David Tepper 2017-06-30 Sold Out 1.7%$31.75 - $34.34 $ 36.269%0
George Soros 2017-06-30 Sold Out 0.03%$31.75 - $34.34 $ 36.269%0
John Paulson 2017-06-30 Sold Out 0.19%$31.75 - $34.34 $ 36.269%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -5.65%0.12%$31.15 - $34.63 $ 36.269%42,835,523
Ken Fisher 2017-03-31 Add 1.72%0.03%$31.15 - $34.63 $ 36.269%32,759,530
T Rowe Price Equity Income Fund 2017-03-31 Reduce -11.33%0.23%$31.15 - $34.63 $ 36.269%12,325,000
Charles Brandes 2017-03-31 Add 14.16%0.38%$31.15 - $34.63 $ 36.269%6,018,005
David Tepper 2017-03-31 Reduce -37.19%1.03%$31.15 - $34.63 $ 36.269%3,021,000
NWQ Managers 2017-03-31 Reduce -42.39%0.43%$31.15 - $34.63 $ 36.269%1,313,554
Joel Greenblatt 2017-03-31 Add 24.40%0.08%$31.15 - $34.63 $ 36.269%944,660
Dodge & Cox 2017-03-31 Reduce -9.22%$31.15 - $34.63 $ 36.269%678,070
Kahn Brothers 2017-03-31 Reduce -22.39%1.06%$31.15 - $34.63 $ 36.269%667,633
Mario Gabelli 2017-03-31 Reduce -1.02%$31.15 - $34.63 $ 36.269%485,466
John Paulson 2017-03-31 Add 15.70%0.03%$31.15 - $34.63 $ 36.269%407,500
Ronald Muhlenkamp 2017-03-31 Reduce -2.80%0.01%$31.15 - $34.63 $ 36.269%33,034
George Soros 2017-03-31 New Buy0.03%$31.15 - $34.63 $ 36.269%31,200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XSWX:NOVN, XSWX:ROG, NYSE:ABBV, NYSE:MRK, XPAR:SAN, NYSE:BMY, XTER:BAYA, NYSE:LLY, LSE:GSK, LSE:AZN, NYSE:JNJ, TSE:4519, TSE:4503, TSE:4578, TSE:4568, HKSE:01093, TSE:4528, TSE:4151, MIL:REC, BOM:500087 » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing close to 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

US Market Indexes Mixed on Friday, Higher for the Week Dow Jones closes at 25,219.38
U.S. market indexes were mixed on Friday. The Dow Jones Industrial Average closed at 25,219.38 for a gain of 19.01 points or 0.08%. The S&P 500 closed at 2,732.22 for a gain of 1.02 points or 0.04%. The Nasdaq Composite closed at 7,239.47 for a loss of -16.96 points or -0.23%. The VIX Volatility Index was higher at 19.39 for a gain of 0.26 points or 1.36%. Read more...
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
The Quest to Develop the First Alzheimer’s Disease Treatment The reasons Pfizer recently decided to stop pursuing neurological disease research and what to look forward to in the near future regarding Alzheimer's disease treatments
The excitement Read more...
Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Investor Expectations to Drive Momentum within QCR, Bridge, Enterprise Financial Services, Hewlett Packard Enterprise, Pfizer, and The Finish Line — Discovering Underlying Factors of Influence
US Market Indexes Report Another Day of Losses Dow Jones closes at 26,076.89
U.S. market indexes were lower on Tuesday. The Dow Jones Industrial Average closed at 26,076.89 for a loss of -362.59 points or -1.37%. The S&P 500 closed at 2,822.43 for a loss of -31.10 points or -1.09%. The Nasdaq Composite closed at 7,402.48 for a loss of -64.02 points or -0.86%. The VIX Volatility Index was higher at 14.79 for a gain of 0.95 points or 6.86%. Read more...
Thinking about Investing in Apple, Amazon.com, Gilead Sciences, McDonald's or Pfizer?
US Market Indexes Close at New Highs on Friday Positive GDP report helps stocks to gain
U.S. market indexes gained on Friday. The Dow Jones Industrial Average closed at 26,616.71 for a gain of 223.92 points or 0.85%. The S&P 500 Index closed at 2,872.87 for a gain of 33.62 points or 1.18%. The Nasdaq Composite closed at 7,505.77 for a gain of 94.61 points or 1.28%. The VIX Volatility Index was lower at 11.22 for a loss of -0.36 points or -3.11%. Read more...
These Companies are DOGS. Buy Them Now. This Way 'The Dogs of the Dow' has shown mixed results over the years, but there is a best way to do this
I am not advocating that you invest solely in the Dogs of the Dow. If you want to do so, however, it is pretty darn easy. Simply wait until the end of each year, then select the 10 stocks of the Dow, 30 of which have the highest yield. Invest an equal amount of dollars into each. That’s all there is to it. Next year, do the same thing. Rinse and repeat every year. Read more...
2018 Could Be Hallmark Year For These Two Antifungal Companies Cidara will be completing Phase II trials for antifungal candidate rezafungin this quarter, followed by Scynexis. If approved, the drugs will compete with Merck, Astellas, and Pfizer.
A pair drug companies are undergoing clinical trials in hopes of receiving approval from the Food and Drug Administration for getting their antifungal medicines in front of the public in 2018. Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.33
PFE's PE Ratio is ranked higher than
92% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.21 vs. PFE: 10.33 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 17.68 Max: 34.43
Current: 10.33
7.68
34.43
Forward PE Ratio 12.32
PFE's Forward PE Ratio is ranked higher than
73% of the 73 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. PFE: 12.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.33
PFE's PE Ratio without NRI is ranked higher than
94% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.28 vs. PFE: 10.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 20.01 Max: 34.43
Current: 10.33
9.83
34.43
Price-to-Owner-Earnings 16.09
PFE's Price-to-Owner-Earnings is ranked higher than
81% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.28 vs. PFE: 16.09 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 11.54 Max: 36.49
Current: 16.09
5.44
36.49
PB Ratio 3.55
PFE's PB Ratio is ranked lower than
56% of the 825 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. PFE: 3.55 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.42 Max: 3.82
Current: 3.55
1.32
3.82
PS Ratio 4.19
PFE's PS Ratio is ranked lower than
60% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. PFE: 4.19 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.63 Max: 4.74
Current: 4.19
1.72
4.74
Price-to-Free-Cash-Flow 16.59
PFE's Price-to-Free-Cash-Flow is ranked higher than
72% of the 217 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.63 vs. PFE: 16.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.59 Max: 18.91
Current: 16.59
5.02
18.91
Price-to-Operating-Cash-Flow 14.22
PFE's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.74 vs. PFE: 14.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 12.05 Max: 15.89
Current: 14.22
4.55
15.89
EV-to-EBIT 16.58
PFE's EV-to-EBIT is ranked higher than
60% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.21 vs. PFE: 16.58 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.6 Max: 28.9
Current: 16.58
6.7
28.9
EV-to-EBITDA 11.84
PFE's EV-to-EBITDA is ranked higher than
70% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. PFE: 11.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.4 Max: 17.3
Current: 11.84
4.9
17.3
EV-to-Revenue 4.63
PFE's EV-to-Revenue is ranked lower than
61% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. PFE: 4.63 )
Ranked among companies with meaningful EV-to-Revenue only.
PFE' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.5 Max: 5
Current: 4.63
1.6
5
Shiller PE Ratio 21.92
PFE's Shiller PE Ratio is ranked higher than
76% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.75 vs. PFE: 21.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.05  Med: 16.77 Max: 23.64
Current: 21.92
9.05
23.64
Current Ratio 1.43
PFE's Current Ratio is ranked lower than
74% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. PFE: 1.43 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.51 Max: 3.18
Current: 1.43
0.98
3.18
Quick Ratio 1.15
PFE's Quick Ratio is ranked lower than
69% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. PFE: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.22 Max: 2.86
Current: 1.15
0.74
2.86
Days Inventory 241.71
PFE's Days Inventory is ranked lower than
88% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.37 vs. PFE: 241.71 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 241.71
185.33
344.63
Days Sales Outstanding 69.48
PFE's Days Sales Outstanding is ranked higher than
56% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.67 vs. PFE: 69.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 69.48
56.83
106.89
Days Payable 113.02
PFE's Days Payable is ranked higher than
72% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.56 vs. PFE: 113.02 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 113.02
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.59
PFE's Dividend Yield % is ranked higher than
86% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. PFE: 3.59 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.7 Max: 10.4
Current: 3.59
2.9
10.4
Dividend Payout Ratio 0.78
PFE's Dividend Payout Ratio is ranked lower than
62% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. PFE: 0.78 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 0.78
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked higher than
53% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.75
PFE's Forward Dividend Yield % is ranked higher than
86% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. PFE: 3.75 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.37
PFE's 5-Year Yield-on-Cost % is ranked higher than
90% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. PFE: 5.37 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.54 Max: 15.57
Current: 5.37
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.00 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.15 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.18
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. PFE: 1.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.4 Max: 9.98
Current: 1.18
0.53
9.98
Price-to-Median-PS-Value 1.16
PFE's Price-to-Median-PS-Value is ranked lower than
53% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. PFE: 1.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.06 Max: 3.28
Current: 1.16
0.44
3.28
Earnings Yield (Greenblatt) % 6.03
PFE's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 868 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.18 vs. PFE: 6.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.8 Max: 14.9
Current: 6.03
3.5
14.9
Forward Rate of Return (Yacktman) % 2.92
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 411 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.51 vs. PFE: 2.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12.2 Max: 23.3
Current: 2.92
2.5
23.3

More Statistics

Revenue (TTM) (Mil) $52,546.00
EPS (TTM) $ 3.51
Beta1.06
Short Percentage of Float0.96%
52-Week Range $31.67 - 39.43
Shares Outstanding (Mil)5,960.71

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 54,214 55,043 55,380
EBIT (Mil $) 19,446 21,483 21,509
EBITDA (Mil $) 23,512 24,450 23,452
EPS ($) 2.90 3.09 3.18
EPS without NRI ($) 2.90 3.09 3.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.80%
Dividends per Share ($) 1.37 1.42 1.50

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}